Clinical implications of pharmacokinetics of sunitinib malate and N-desethyl-sunitinib plasma concentrations for treatment outcome in metastatic renal cell carcinoma patients

In this study, we examined the association between the pharmacokinetics (PK) level of sunitinib malate (SU) and its metabolite N-desethyl-sunitinib (DSU) in terms of adverse events (AEs) and clinical outcomes in patients with metastatic renal cell carcinoma (mRCC). The PK of sunitinib (SU and DSU) w...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Oncotarget
Päätekijät: Numakura, Kazuyuki, Fujiyama, Nobuhiro, Takahashi, Makoto, Igarashi, Ryoma, Tsuruta, Hiroshi, Maeno, Atsushi, Huang, Mingguo, Saito, Mitsuru, Narita, Shintaro, Inoue, Takamitsu, Satoh, Shigeru, Tsuchiya, Norihiko, Niioka, Takenori, Miura, Masatomo, Habuchi, Tomonori
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Impact Journals LLC 2018
Aiheet:
Research Paper
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC5982748/
https://ncbi.nlm.nih.gov/pubmed/29861870
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.25423
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia